You have read all your free articles, to continue reading subscribe to read the rest of this content.
Nordic Nanovector has entered into a collaboration with LegoChem Biosciences, a South Korea-based biopharmaceutical company, to develop novel CD37-targeting antibody-drug conjugates (ADCs) for the treatment of leukaemias. Leukemias are orphan diseases with a significant unmet medical need, represAlready a subscriber Login You have read all your free articles, to continue…
AstraZeneca and Eli Lilly and Company have signed a worldwide agreement to co-develop MEDI1814, an antibody selective for amyloid-beta 42 (Aβ42), which is currently in Phase I trials as a potential disease-modifying treatment for Alzheimer’s disease (AD). This agreement builds on the existing Already a subscriber Login You have read…
The Swedish government will initiate a million investment in a center for clinical trials, based in Gothenburg. This was announced by the Minister for Education, Jan Björklund, during his summer speech on August 3. The aim with the investment is to strengthen the co-ordination between the pharmaAlready a subscriber Login…
Nordic Nanovector has enrolled the final two patients into the second safety cohort of its Phase 1 Archer-1 (LYMRIT 37-07) trial investigating safety and preliminary efficacy of Betalutin (177Lu lilotomab satetraxetan) in combination with rituximab in 2nd-line follicular lymphoma (2L FL). The dosAlready a subscriber Login You have read all…
